Global diagnostics manufacturer opens new Houston facility, headquarters

moving in

Healgen Scientific opened its new headquarters in Houston last week. Photo courtesy of Healgen

A global health care company has cut the ribbon on its new facility and headquarters in Houston.

Healgen Scientific, which manufacturers diagnostic products for infectious diseases, toxicology, oncology, and more, opened the facility last week. Operating as the company's new headquarters, the location is the first manufacturing facility in Houston for Healgen. The company currently has around 120 employees in the U.S. and is expected to create over 200 new jobs in the next three years

“This new facility in Houston uses very innovative technology that will precisely diagnose viruses or diseases so people can be confident in the results they are receiving,” Bingliang Fang, CEO of Healgen Scientific, says in a release. “Here, Healgen is able to produce quality tests on a very large scale—nearly a half million per day. We are proud to provide made in the USA products with a commitment to using local materials, employing local residents and being an integral part of the community.”

Amid the COVID-19 pandemic, Healgen Scientific teamed up with Siemens Healthcare Diagnostics Inc. on a Rapid COVID-19 Antigen Self-Test. Today, over 2 billion Rapid COVID-19 Antigen Self-Test Kits have been used worldwide.

With 325 automated production lines around the world, Healgen's facilities have a daily production capacity of more than 22 million health care tests. Recently, the company moved 15 of these production lines to the U.S., investing over $100 million in three large-scale manufacturing and warehouse facilities in New York, New Jersey, and Texas. The facility in Houston will also produce RSV tests later in the year.

“We welcome you to our great city,” says Chris Hollins, city controller, City of Houston Controller’s Office. “This is a city, and a state, of business and of commerce. We’re excited that hundreds of jobs are on the way because of the investment of Healgen and the Fang family, and we’re grateful for your presence. On behalf of more than 2 million Houstonians, we applaud Healgen Scientific LLC on bringing world-class innovation and disease management to the United States.”

Healgen cut the ribbon on its newest facility last week. Photo courtesy of Healgen

The new center is specifically designed to allow patients to be on the cutting edge of testing brand-new therapies that could save their lives.

Houston cancer-fighting organization launches center to support early clinical trials

new to hou

Cancer treatment in Houston just became even more promising — and forward-thinking.

Phase 1 clinical trials are necessary to prove the efficacy in humans of treatments that have appeared promising in lab trials. In the name of cancer-fighting innovation, Baylor College of Medicine’s Dan L. Duncan Comprehensive Cancer Center has launched the Albert and Margaret Alkek Foundation Center for Experimental Therapeutics.

The new center is specifically designed to allow patients to be on the cutting edge of testing brand-new therapies that could save their lives.

“Clinical trials are critical for advancing the field of oncology and improving outcomes for cancer patients. Phase 1 trials are the first step in bringing innovative therapies to the clinic,” says Dr. Benjamin Musher, Barry S. Smith endowed professor at Baylor and medical director of medical oncology at the Duncan Cancer Center McNair Campus, in a news release. “Our new program will build on the success of previous phase 1 trials at Baylor and provide robust infrastructure to offer more clinical trial opportunities to our patients.”

The Alkek Foundation Center’s team practices across all specialty areas, allowing a broad swath of the Cancer Center’s patients to take part and to continue to receive care from the sub-specialty doctors they know and trust. And even if they aren’t already being treated at Baylor, physicians from outside Baylor can refer patients to the program through a smooth process.

“We are excited to offer novel research treatment options to our cancer patients at our state-of-the-art unit,” says Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center and senior associate dean of cancer programs at Baylor. “This program will increase the scope of our research while giving the cancer patients in our community access to first in human and cutting-edge clinical trials.”

Patients will be treated at Duncan Cancer Center’s clinical home, Baylor St. Luke’s Medical Center’s O’Quinn Medical Tower at the McNair Campus. As interim dean of research and dean of the Graduate School of Biomedical Sciences at Baylor, Carolyn Smith says, with the new center, Baylor is “advancing medicine by taking innovations made in the lab and moving them to the bedside.”

The debut trial to take place at the center enrolled its first patient this month. It will test a novel therapy that targets a mutation commonly found in pancreatic and colorectal cancers.

“Phase 1 oncology clinical trials provide patients early access to cutting-edge therapeutics and immunotherapies that are not widely available. Patients in these trials are often selected because their tumors have a molecular feature that is targeted by these therapies,” says Dr. S. Gail Eckhardt, who is Baylor’s Albert and Margaret Alkek endowed chair and serves as associate dean for experimental therapeutics at Baylor and associate director of translational research at the Duncan Cancer Center.

MD Anderson’s goal with the new Institute for Data Science in Oncology is to advance collaborative projects that will bring the power of data science to every decision made at the hospital. Photo via mdanderson.org

Houston organization introduces inaugural cancer-fighting cohort of data sciences, experts

new to hou

The University of Texas MD Anderson Cancer Center is one step closer to ending cancer thanks to its new institute that's focused on data science.

MD Anderson’s goal with the new Institute for Data Science in Oncology (IDSO) is to advance collaborative projects that will bring the power of data science to every decision made at the hospital. And now, the IDSO has announced its inaugural cohort of 33 scientists, clinicians, and staff that will bring it to life, joining the already appointed leadership and focus area co-leads.

“By engaging diverse expertise across all of our mission areas, we will enhance the rich and productive data science ecosystem at MD Anderson to deliver transformational impact for patients,” David Jaffray, Ph.D., director of IDSO and chief technology and digital officer at MD Anderson, says in a press release.

The focus areas for the IDSO are quantitative pathology and medical imaging; single-cell analytics; computational modeling for precision medicine; decision analytics for health; and safety, quality, and access.

The IDSO Affiliates, as they are known, are a mix of existing contributors to the IDSO and team members who were recruited specifically for their expertise in data science. The affiliates were chosen to fulfill a two-year term, during which they will focus on IDSO projects related to the focus areas above. The diverse roster of professionals includes:

“Our affiliates bring expertise, perspectives and commitment from across the institution to foster impactful data science in order to tackle the most urgent needs of our patients and their families,” said Caroline Chung, M.D., director of Data Science Development and Implementation for IDSO and chief data officer at MD Anderson. “People and community are at the heart of our efforts, and establishing the IDSO Affiliates is an exciting step in growing the most impactful ecosystem for data science in the world.”

A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

TMC names inaugural cohort for unique accelerator with UK

coming to HOU

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.
Houston-based Moleculin Biotech now has four different oncology treatment currently in trials. Getty Images

Houston cancer-fighting biotech company introduces its 4th ongoing clinical trial

health report

A Houston-based biotech company has wrapped up enrollment for its most recent clinical trial of its cancer-fighting drug.

Moleculin Biotech Inc. (Nasdaq: MBRX) has launched its fourth ongoing trial — this time focusing on Cutaneous T-Cell Lymphoma, or CTCL, treatment. The company's other three trials include treatment for glioblastoma, an aggressive brain cancer, pancreatic cancer, one of the most virulent killers in oncology, and acute myeloid leukemia, or AML.

To treat these various types of cancers, Moleculin has a several drugs it's in preclinical or clinical trials testing — most biotech companies have only one they focus on. WP1220 is the drug that will be used in this trial for topical CTCL treatment of the cancer's resulting skin lesions.

"We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "especially one that may avoid significant unwanted side effects."

WP1220 is what's known as a p-STAT3 inhibitor. STAT3 is a transcription factor that encourages tumor development. Moleculin's technology directly attacks the tumor, but also quiets T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

"This proof of concept, if successful, could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor," Klemp continues. "We are pleased with how quickly this trial reached full recruitment and we are hopeful to be able to announce results from this trial yet this year."

Klemp founded the company in 2007, and Moleculin went public in 2016. Now, with the company's four clinical trials, Moleculin is even closer to saving lives with its products.

"Notwithstanding the relatively rare nature of CTCL, we believe showing activity with one of our STAT3 inhibitors, within our WP1066 family of molecules, could be an indicator of both the value of p-STAT3 as a target and the potential for our drugs in other cancers where STAT3 is highly activated," Klemp says in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston hailed as one of America's 10 best cities for startups

Startup Report

Houston's favorable economic climate is enticing new opportunities for entrepreneurship and growth, and now the city is being hailed as the 7th-best U.S. city for starting a business.

The recognition comes in CommercialCafe's recent "Best Cities for Startups" report, published December 10. The study analyzed large U.S. cities across two population categories – cities with more than 1 million residents and cities with populations between 500,000 and 1 million residents. The report analyzed relevant metrics such as office or coworking costs, Kickstarter funding success, startup density, and survival rates, among others.

Across the biggest U.S. cities with over a million residents, Phoenix, Arizona landed on top as the No. 1 best place to start a new business.

The report's findings revealed 10.6 percent of all businesses in Houston are startups that have been active for less than a year. These new businesses have a survival rate of 64.5 percent, meaning just under two-thirds of all startups in the city will still be running up to five years after they were first established.

Over the last five years, the number of new businesses established in Houston has grown nearly 15 percent. CommercialCafe said new businesses in cities with high startup growth rates tend to "attract top talent" which can eventually lead to securing "vital funding for expansion."

Independent professionals – also known as freelancers – are another crucial resource for new businesses that may need "specialized services" for a fixed amount of time, the report said. Houston's freelance workforce has grown about 9 percent from 2019-2023, and the analysis found there were 97,295 freelancers working in Houston in 2023, compared to 89,528 in 2019.

"Generally, cities in the South and Southwest have experienced strong growth during the surveyed period, in contrast to California cities like Los Angeles and San Diego, where the share of freelancers and gig workers has either stagnated or slightly declined," the report said.

Houston boasts the second-cheapest office space rent nationally, the report found. The average asking price for a 1,000-square-foot workspace (for five employees) in the city added up to $27,124 annually. For startups that want greater flexibility for their workers, the annual cost for a coworking space for the same number of employees in Houston came out to $13,200, which is the fourth-most affordable rate in the U.S.

Other Texas cities with attractive economic environments for startups

Texas, as a whole, is one of the strongest states for starting a new business. Other than Houston, San Antonio (No. 2), Dallas (No. 3), and Fort Worth (No. 4) were also recognized among the top 10 best places to start a business in the category of U.S. cities with more than a million residents.

Austin topped a separate ranking of best cities to start a business with 500,000 to 1 million residents.

"Specifically, the Texas capital was the frontrunner for indicators that looked at the overall share of startups within the local economy, as well as growth rates in five years (2019 to 2023)," the report said. "On top of that, Austin also topped the rankings for its percentage of college-educated residents and its consulting firms, which provide vital support for burgeoning enterprises."

The top 10 best cities to start a new business are:

  • No. 1 – Phoenix, Arizona
  • No. 2 – San Antonio, Texas
  • No. 3 – Dallas, Texas
  • No. 4 – Fort Worth, Texas
  • No. 5 – Jacksonville, Florida
  • No. 6 – San Diego, California
  • No. 7 – Houston, Texas
  • No. 8 – Philadelphia, Pennsylvania
  • No. 9 – Chicago, Illinois
  • No. 10 – Los Angeles, California
---

This article originally appeared on CultureMap.com.

Top Houston space news of 2025 soars with NASA deals, lunar missions

Year in Review

Editor's note: As 2025 comes to a close, we're looking back at the stories that defined Houston innovation this year. The space tech sector soared with companies landing huge NASA contracts and furthering their lunar missions. Here are the 10 biggest Houston space tech stories of the year:

Houston native picked for 2025 class of NASA astronaut candidates

Houston native Anna Menon, posing below the first A in “NASA,” is one of 10 new NASA astronaut candidates. Photo courtesy NASA.

NASA has selected 10 new astronaut candidates, including one whose hometown is Houston, for its 2025 training class. The candidates will undergo nearly two years of training before they can assume flight assignments.

Intuitive Machines lands $9.8M to complete orbital transfer vehicle

Intuitive Machines expects to begin manufacturing and flight integration on its orbital transfer vehicle as soon as 2026. Photo courtesy Intuitive Machines.

Houston-based Intuitive Machines, which rang the NASDAQ opening bell July 31, secured a $9.8 million Phase Two government contract for its orbital transfer vehicle. The contract will push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin.

Houston tech company tapped by NASA for near space initiative

Intuitive Machines is among four companies awarded contracts for NASA’s Near Space Network. Photo via intuitivemachines.com

In January, Intuitive Machines nailed down a NASA deal to expand the agency’s communications network for spacecraft. Additionally, NASA completed the first round of “human in the loop” testing for Intuitive Machines’ Moon RACER lunar terrain vehicle at the agency’s Johnson Space Center. RACER (Reusable Autonomous Crewed Exploration Rover) is one of three commercially developed unpressurized lunar terrain vehicles being considered for NASA’s Artemis lunar initiative.

Texas Space Commission doles out $5.8 million to Houston companies

Axiom Space and FluxWorks are the latest Houston-area companies to receive funding from the Texas Space Commission. Photo via Getty Images.

Two Houston-area companies landed more than $5.8 million in funding from the Texas Space Commission. The commission granted up to $5.5 million to Houston-based Axiom Space and up to $347,196 to Conroe-based FluxWorks in June 2025. The two-year-old commission previously awarded $95.3 million to 14 projects. A little over $34 million remains in the commission-managed Space Exploration and Aeronautics Research Fund.

Houston company awarded $2.5B NASA contract to support astronaut health and space missions

NASA has awarded KBR a five-year, $2.5 billion Human Health and Performance Contract. Photo courtesy NASA.

Houston-based technology and energy solution company KBR was awarded a $2.5 billion NASA contract to support astronaut health and reduce risks during spaceflight missions. Under the terms of the Human Health and Performance Contract 2, KBR will provide support services for several programs, including the Human Research Program, International Space Station Program, Commercial Crew Program, Artemis campaign and others. This will include ensuring crew health, safety, and performance; occupational health services and risk mitigation research for future flights.

Houston engineering firm lands $400M NASA contract

Bastion Technologies has been tapped to provide safety and mission services for NASA's Marshall Space Flight Center in Alabama. Photo via nasa.gov.

NASA granted Houston-based Bastion Technologies Inc. the Safety and Mission Assurance II (SMAS II) award with a maximum potential value of $400 million. The award stipulates that the engineering and technical services company provide safety and mission services for the agency’s Marshall Space Flight Center in Huntsville, Alabama.

Houston startups win NASA funding for space tech projects

Houston startups were recently named among the nearly 300 recipients that received a portion of $44.85 million from NASA to develop space technology. Photo via NASA/Ben Smegelsky

Three Houston startups were granted awards from NASA in July 2025 to develop new technologies for the space agency. The companies were among nearly 300 recipients that received a total agency investment of $44.85 million through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I grant programs.

Texas Republicans are pushing to move NASA headquarters to Houston

Here's why Texas Republicans think NASA's headquarters should move to Texas in 2028. File photo.

Two federal lawmakers from Texas spearheaded a campaign to relocate NASA’s headquarters from Washington, D.C., to the Johnson Space Center in Houston’s Clear Lake area. Houston faces competition on this front, though, as lawmakers from two other states are also vying for this NASA prize. With NASA’s headquarters lease in D.C. set to end in 2028, U.S. Sen. Ted Cruz, a Texas Republican, and U.S. Rep. Brian Babin, a Republican whose congressional district includes the Johnson Space Center, wrote a letter to President Trump touting the Houston area as a prime location for NASA’s headquarters.

Intuitive Machines to acquire NASA-certified deep space navigation company

Intuitive Machines will acquire Kinetx, which marks its entry into the precision navigation and flight dynamics segment of deep space operations. Photo via Getty Images.

In August 2025, Intuitive Machines agreed to buy Tempe, Arizona-based aerospace company KinetX for an undisclosed amount. The deal is expected to close by the end of this year. KinetX specializes in deep space navigation, systems engineering, ground software and constellation mission design. It’s the only company certified by NASA for deep space navigation. KinetX’s navigation software has supported both of Intuitive Machines’ lunar missions.

Axiom Space launches semiconductor and astronaut training initiatives

Axiom Space chief astronaut Michael López-Alegría (left) trains with Axiom’s new “Project Astronaut,” Emiliano Ventura. Photo courtesy of Axiom Space.

In fall 2025, Axiom Space, a Houston-based commercial spaceflight and space infrastructure company, launched initiatives in two very different spheres — semiconductors and astronaut training.

Paraplegic engineer becomes first wheelchair user to blast into space

Space News

A paraplegic engineer from Germany blasted off on a dream-come-true rocket ride with five other passengers Saturday, December 20, leaving her wheelchair behind to float in space while beholding Earth from on high.

Severely injured in a mountain bike accident seven years ago, Michaela Benthaus became the first wheelchair user in space, launching from West Texas with Jeff Bezos’ company Blue Origin. She was accompanied by a retired SpaceX executive also born in Germany, Hans Koenigsmann, who helped organize and, along with Blue Origin, sponsored her trip. Their ticket prices were not divulged.

An ecstatic Benthaus said she laughed all the way up — the capsule soared more than 65 miles (105 kilometers) — and tried to turn upside down once in space.

“It was the coolest experience,” she said shortly after landing.

The 10-minute space-skimming flight required only minor adjustments to accommodate Benthaus, according to the company. That’s because the autonomous New Shepard capsule was designed with accessibility in mind, “making it more accessible to a wider range of people than traditional spaceflight,” said Blue Origin’s Jake Mills, an engineer who trained the crew and assisted them on launch day.

Among Blue Origin’s previous space tourists: those with limited mobility and impaired sight or hearing, and a pair of 90-year-olds.

For Benthaus, Blue Origin added a patient transfer board so she could scoot between the capsule’s hatch and her seat. The recovery team also unrolled a carpet on the desert floor following touchdown, providing immediate access to her wheelchair, which she left behind at liftoff. She practiced in advance, with Koenigsmann taking part with the design and testing. An elevator was already in place at the launch pad to ascend the seven stories to the capsule perched atop the rocket.

Benthaus, 33, part of the European Space Agency’s graduate trainee program in the Netherlands, experienced snippets of weightlessness during a parabolic airplane flight out of Houston in 2022. Less than two years later, she took part in a two-week simulated space mission in Poland.

“I never really thought that going on a spaceflight would be a real option for me because even as like a super healthy person, it’s like so competitive, right?” she told The Associated Press ahead of the flight.

Her accident dashed whatever hope she had. “There is like no history of people with disabilities flying to space," she said.

When Koenigsmann approached her last year about the possibility of flying on Blue Origin and experiencing more than three minutes of weightlessness on a space hop, Benthaus thought there might be a misunderstanding. But there wasn't, and she immediately signed on.

It’s a private mission for Benthaus with no involvement by ESA, which this year cleared reserve astronaut John McFall, an amputee, for a future flight to the International Space Station. The former British Paralympian lost his right leg in a motorcycle accident when he was a teenager.

An injured spinal cord means Benthaus can’t walk at all, unlike McFall who uses a prosthetic leg and could evacuate a space capsule in an emergency at touchdown by himself. Koenigsmann was designated before flight as her emergency helper; he and Mills lifted her out of the capsule and down the short flight of steps at flight’s end.

“You should never give up on your dreams, right?” Benthaus urged following touchdown.

Benthaus was adamant about doing as much as she could by herself. Her goal is to make not only space accessible to the disabled, but to improve accessibility on Earth too.

While getting lots of positive feedback within “my space bubble,” she said outsiders aren't always as inclusive.

“I really hope it’s opening up for people like me, like I hope I’m only the start," she said.

Besides Koenigsmann, Benthaus shared the ride with business executives and investors, and a computer scientist. They raised Blue Origin’s list of space travelers to 86.

Bezos, the billionaire founder of Amazon, created Blue Origin in 2000 and launched on its first passenger spaceflight in 2021. The company has since delivered spacecraft to orbit from Cape Canaveral, Florida, using the bigger and more powerful New Glenn rocket, and is working to send landers to the moon.

View All Listings